Atlas Trials

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Clinical trial NCT05200143 · TERMINATED

Trial details

NCT number
NCT05200143
Sponsor
Providence Health & Services
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory Cutaneous Melanoma
Start date
2022-06-08
Primary completion
2023-09-11
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.